However, it is currently impossible to obtain precise estimates of the long-term risk of the more serious adverse effects such as pancreatitis or precancerous pancreatic lesions that have been claimed by some to be associated with GLP1-based therapies (21). This evidence concerns the gene GCG and pancreatitis.